-
2007年白细胞介素(IL)-35被确立为一个免疫抑制性细胞因子,此后很快成为自身免疫疾病研究热点[1-2]。IL-35由调节性T细胞(Tregs)、调节性B细胞(Bregs)、CD4+ Tregs分泌[1, 3],在许多体内外疾病模型,如急性胰腺炎[4]、胶原诱导性关节炎(CIA)[5]、牙周炎[6]、过敏性鼻炎、哮喘[7]以及冠心病中,均能抑制T细胞的扩增和免疫功能,且可以促进小鼠和人类Tregs发挥抑制作用[8-9]。而近些年研究表明卡介苗(BCG)可以作为免疫调节剂[10]和佐剂[11],针对自身免疫性疾病,如多发性硬化症、胰岛素依赖型糖尿病[12]、哮喘[13]等发挥免疫调节作用,许多实验[14-15]证实BCG可以加强Treg免疫反应,抑制一些炎性介质的产生[16]。既往已有研究[17]在小鼠眼睛玻璃体腔接种重组pcDNA3.1-IL-35质粒,以观察其角膜表达的移植物排斥相关细胞因子,以及在新生小鼠体内接种IL-12重组BCG干预实验性哮喘模型等[18],均表明重组质粒及重组BCG在体内发挥免疫作用的可实施性。本研究利用基因工程技术构建IL-35重组BCG,其分泌IL-35又保留了BCG的免疫调节作用,协同增强其免疫源性,为进一步探讨IL-35及BCG的生物学功能和开发新用途奠定了基础。
IL-35重组卡介苗的构建及鉴定
Construction and identification of the IL-35-BCG recombinant vaccine
-
摘要:
目的构建分泌性表达白细胞介素(IL)-35真核载体pZM03(pBudCE4.1/GLS/IL35/OriM)-重组卡介苗(BCG)。 方法在化学合成的IL-35基因片段中插入pBudCE4.1/GLS/OriM,将合成后序列插入到IL-12真核共表达载体pBudCE4.1/GLS/IL12/OriM的质粒酶切回收产物pBudCE4.1/GLS/OriM中,构建表达IL-35的穿梭/共表达质粒重组质粒pZM03(pBudCE4.1/GLS/IL35/OriM),再以重组质粒电转化到BCG,构建表达IL-35和BCG的重组pBudCE4.1/GLS/IL35/OriM-BCG。 结果重组质粒pZM03(pBudCE4.1/GLS/IL35/OriM)经PCR扩增、测序鉴定,以及在CHO 293T细胞中表达产物的Western blotting检测,从转录和翻译水平对目标基因产物进行检测验证,pBudCE4.1/GLS/IL35/OriM-BCG在细胞水平经抗酸染色验证,证实基因IL-35正确插入载体pBudCE4.1/GLS/OriM中,且pBudCE4.1/GLS/IL35/OriM-BCG构建成功。 结论重组质粒pBudCE4.1/GLS/IL35/OriM-BCG可正确表达IL-35,为进一步研究IL-35功能及其应用价值奠定了良好的基础。 Abstract:ObjectiveTo construct the recombinant eukaryotic expression vector pZM03 (pBudCE4.1/GLS/IL35/OriM) containing secretory protein of interleukin 35 (IL-35)-bacillus calmette guerin (BCG)recombinant vaccine. MethodsThe chemically synthesized IL-35 gene fragment was cloned into the pBudCE4.1/GLS/OriM, the pBudCE4.1/GLS/IL35/OriM was obtained from the pBudCE4.1/GLS/IL12/OriM, and both of above was used to construct the co-expression vector pZM03 (pBudCE4.1/GLS/IL35/OriM).The recombinant plasmid pZM03 was electrotransformated into the BCG to construct the recombinant co-expression of IL-35 and BCG plasmid pBudCE4.1/GLS/IL35/OriM-BCG. ResultsThe results of the detection of gene, transcription, translation and cellular levels, which included the PCR, sequencing, Western blotting and acid-fast staining methods, showed that the pBudCE4.1/GLS/IL35/OriM-BCG was successfully constructed. ConclusionThe recombinant plasmid pBudCE4.1/GLS/IL35/OriM-BCG can correctly express IL-35, which lays a good foundation for further research on the function and application value of IL-35. -
Key words:
- bacillus calmette guerin /
- interleukin-35 /
- recombinant plasmid
-
[1] SAWANT DV, HAMILTON K, VIGNALI DA, et al.Interleukin-35:expanding its job profile[J].J Interferon Cytokine Res, 2015, 35(7):499. doi: 10.1089/jir.2015.0015 [2] THIOLAT A, DENYS A, PETIT M, et al.Interleukin-35 gene therapy exacerbates experimental rheumatoid arthritis in mice[J].Cytokine, 2014, 69(1):87. [3] WANG RX, YU CR, DAMBUZA IM, et al.Interleukin-35 induces regulatory B cells that suppress autoimmune disease[J].Nat Med, 2014, 20(6):633. doi: 10.1038/nm.3554 [4] ZHANG YL, ZHOU XY, GUO XY, et al.Association between serum interleukin-35 levels and severity of acute pancreatitis[J].Int J Clin Exp Med, 2015, 8(5):7430. [5] FILKOVA M, VEMEROVA Z, HULEJOVA H, et al.Pro-in Tammatory effects of interleukin-35 in rheumatoid arthritis[J].Cytokine, 2015, 73(1):36. [6] KOSEOGLU S, SAGLAM M, PEKBAGRIYANIK T, et al.Level of interleukin-35 ingingival crevicular Tuid, saliva, and plasma in periodontal disease and health[J].J Periodontol, 2015, 86(8):964. doi: 10.1902/jop.2015.140666 [7] DING LF, CHEN Q, LI L, et al.Effects of sublingual immunotherapy on serum IL-17 and IL-35 levels in children with allergic rhinitis or asthma[J].Zhongguo Dang Dai Er Ke Za Zhi, 2014, 16(12):1206. [8] COLLISON LW, PILLAI MR, CHATURVEDI V, et al.Regulatory T cell suppression is potentiated by target T cells in a cell contact:IL-35-and IL-10-dependent manner[J].J Immunol, 2009, 182(10):6121. doi: 10.4049/jimmunol.0803646 [9] COLLISON LW, WORKMAN CJ, KUO TT, et al.The inhibitory cytokine IL-35 contributes to regulatory T-cell function[J].Nature, 2007, 450(7169):566. doi: 10.1038/nature06306 [10] TIAN X, TIAN X, HUO R, et al.Bacillus Calmette-Guerin alleviates airway inflammation and remodeling by preventing TGF-beta1 induced epithelial-mesenchymal transition[J].Hum Vaccin Immunother, 2017, 13(8):1758. doi: 10.1080/21645515.2017.1313366 [11] MOHAMMADI SV, REZAEI A, ANDALIB A, et al.Immunomodulatory effects of adjuvants CPG, MPLA, and BCG on the Derp2-induced acute asthma at early life in an animal model of BALB/c mice[J].Inflammation, 2017, 40(1):259. [12] KOWALEWICZ KM, LOCHT C.BCG and protection against inflammatory and auto-immune diseases[J].Expert Rev Vaccines, 2017, 16(7):1. [13] SOUZA MA, CRUZ AA.BCG vaccination and reduced risk of asthma[J].J Bras Pneumol, 2010, 36(3):275. doi: 10.1590/S1806-37132010000300001 [14] CUI Y, CHOI IS, KOH YA, et al.Effects of combined BCG and DHEA treatment in preventing the development of asthma[J].Immunol Invest, 2008, 37(3):191. [15] KE X, HUANG J, CHEN Q, et al.Protective effects of combined Mycobacterium bovis BCG and interleukin-12 vaccination on airway inflammation in a murine model of allergic asthma[J].Clin Invest Med, 2010, 33(3):196. doi: 10.25011/cim.v33i3.13726 [16] DENG Y, LI W, LUO Y, et al.Inhibition of IFN-gamma promotes anti-asthma effect of Mycobacterium bovis Bacillus Calmette-Guerin neonatal vaccination:a murine asthma model[J].Vaccine, 2014, 32(18):2070. doi: 10.1016/j.vaccine.2014.02.007 [17] HOU C, WU Q, OUGYANG C, et al.Effects of an intravitreal injection of interleukin-35-expressing plasmid on pro-infl ammatory and anti-infl ammatory cytokines[J].Int J Mol Med, 2016, 38(3):713. doi: 10.3892/ijmm.2016.2688 [18] 邓昱.IL-12+重组卡介苗新生期接种干预实验性哮喘模型的作用及其机制研究[D].重庆: 重庆医科大学, 2010. [19] CASTELLANI ML, ANGEIANAKI A, FELACO P, et al.IL-35, an antiinflammatory cytokine which expands CD4+CD25+ Treg cells[J].J Biol Regul Homeost Agents, 2010, 24(2):131. [20] TARIQUE M, SAINI C, NAQVI RA, et al.Increased IL-35 producing Tregs and CD19+IL-35+ cells are associated with disease progression in leprosy patients[J].Cytokine, 2017, 91:82. doi: 10.1016/j.cyto.2016.12.011 [21] SHEN H, WANG C, FAN E, et al.Upregulation of interleukin-35 subunits in regulatory T cells in a IL-35 alleviates lipopolysaccharide-Induced acute kidney injury murine model of allergic rhinitis[J].J Otorhinolaryngol, 2014, 76(5):237. [22] ZHAO N, LI H, YAN Y, et al.Mesenchymal stem cells overexpressing IL-35 effectively inhibit CD4+ T cell function[J].Cellular Immunology, 2017, 312:61. doi: 10.1016/j.cellimm.2016.12.001 [23] NIEDBALA W, WEI XQ, CAI B, et al.IL-35 is a novel cytokine withtherapeutic effects against collagen-induced arthritis through the expansion of regulatory T cells and suppression of Th17 cells[J].Eur J Immunol, 2007, 37(11):3021. doi: 10.1002/eji.200737810 [24] ZHANG F, LI MY, LAN YT, et al.Imbalance of Th17/Tregs in rats with smoke inhalation-induced acute lung injury[J].Sci Rep, 2016, 6:21348. doi: 10.1038/srep21348 [25] JIANG S, LI Y, LIN T, et al.IL-35 inhibits angiogenesis through VEGF/Ang2/Tie2 pathway in rheumatoid arthritis[J].Cellular Physiol Biochemistry, 2016, 40(5):1105. doi: 10.1159/000453165 [26] HU L, CHEN C, ZHANG J, et al.IL-35 pretreatment alleviates lipopolysaccharide-induced acute kidney injury in mice by inhibiting NF-κB activation[J].Inflammation, 2017, 40(4):1393. [27] ZHANG B, LIU Y, LAN X, et al.Oral escherichia coli expressing IL-35 meliorates experimental colitis in mice[J].J Transl Med, 2018, 16(1):71. [28] 李忠明.当代新疫苗[M].北京:高等教育出版社, 2001:93. [29] 沈雪艳, 陈三妹, 陈小萍, 等.新生期卡介苗和乙肝疫苗联合接种对哮喘小鼠IFN-γ、IL-4和IL-17A表达的影响[J].中国病理生理杂志, 2018, 34(3):515. doi: 10.3969/j.issn.1000-4718.2018.03.022 [30] 闻玉梅.治疗性疫苗的研究进展[J].中华微生物学和免疫学杂志, 1996, 16(3):155. [31] NASCIMENTO IP, DIAS WO, QUINTILIO W, et al.Neonatal immunization with a single dose of recombinant BCG expressing subunit S1 from pertussis toxin induces complete protection against Bordetella pertussis intracerebral challenge[J].Microbes Infect, 2008, 10(2):198. doi: 10.1016/j.micinf.2007.10.010 [32] 王秋悦.柔嫩艾美耳球虫rhomboid基因重组卡介苗的构建及其免疫保护性研究[D].长春: 吉林大学, 2009.